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REGULATORY T CELLS IN CANINE CANCER 
 
 Numbers of regulatory T cells (Treg) are increased in some human malignancies 
and are often negatively correlated with patient disease-free interval and survival. Canine 
Treg have previously been identified in healthy and cancer-bearing dogs and have found 
to be increased in the blood of dogs with some types of cancer. Moreover, some 
preliminary research indicates that increased numbers of Treg and decreased numbers of 
CD8
+
 T cells in the blood of dogs with osteosarcoma (OSA) are associated with 
decreased survival. The aim of this project was to examine Treg distributions in dogs 
with cancer compared to normal dogs and to determine any association between Treg 
numbers and patient outcome.  Additionally, we sought to determine if treatment with 
daily low-dose (metronomic) chemotherapy would decrease Treg in dogs with cancer. 
 Pre-treatment Treg populations in blood, tumors, and lymph nodes of dogs with 
OSA were assessed and compared with Treg in blood and lymph nodes of a healthy, 
control population of dogs.  No significant changes in Treg numbers in the blood or 
lymph nodes of the OSA-bearing dogs compared to the control population were 
identified. The dogs with OSA with treated with amputation of the affected limb followed 
by adjunctive chemotherapy.  Treg numbers in the blood or tumor were not associated 
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with outcome but an elevated ratio of CD8
+
 T cells to Treg in the tumor was associated 
with a prolonged disease-free interval and increased survival. These findings suggest that 
changes in number of Treg and effector T cell subset may provide prognostic information 
for canine OSA. 
In mice and humans with advanced cancer, the administration of metronomic 
(daily low dose) cyclophosphamide (CYC) selectively decreases circulating Treg 
numbers and inhibits their function. Protocols containing metronomic CYC likely have 
anti-tumor properties in dogs as well. Despite wide use of metronomic CYC in veterinary 
medicine, its effects on canine Treg have not previously been reported. Dogs with soft 
tissue sarcoma (STS) were administered CYC at 12.5 mg/m
2
 or 15 mg/m
2
 orally once 
daily for 28 days.  Whole blood samples and tumor biopsies were obtained on days 0, 14, 
and 28 to assess changes in T lymphocyte subsets, circulating endothelial cells, and 
tumor microvessel density (MVD). Administration of CYC at 12.5 mg/m
2
/day 
significantly decreased the number of Treg from day 0 to 28, but there was no change in 
the percentage of Treg or tumor MVD.  In dogs that received CYC at 15.0 mg/m
2
/day, 
both the number and percent of Treg as well as tumor MVD were significantly decreased 
over 28 days. These findings suggest that metronomic dosing of CYC may have 
immunomodulatory and antiangiogenic effects in dogs with cancer. 
Taken together the work described in this thesis support the theory that Treg are 
altered in dogs with cancer and that these changes may have prognostic value. 
Additionally, Treg can be decreased in dogs with cancer though administration of 
metronomic doses of CYC; the therapeutic benefit of Treg depletion has yet to be 
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Literature Review and Project Rationale  
 
 Overview of regulatory T cells  
 The existence of immune cells with suppressive activity was first proposed in 
1971 but the concept of regulatory T cells (Treg), as they came to be known, was not 
fully accepted until decades later with the identification of a population of CD4
+
 T cells 
that highly expressed CD25 and prevented autoimmunity in mice.
1,2
  Further research has 
elucidated that natural Treg arise from the thymus and function to maintain tolerance to 
self-antigens, thereby preventing autoimmune diseases.
3
 Natural Tregs are thought to 
exert their inhibitory effects via direct cell to cell contact in a cytokine independent 
fashion.
4
 Treg can be induced in the periphery secondary to increased amounts of the 
cytokine IL-2; this population is known as adaptive Treg. Adaptive Treg are frequently 
up regulated secondary to inflammatory processes such as infection and neoplasia, and 
there is increasing evidence that this increase in Treg with cancer may play a role in 
inhibition of anti-tumor immunity. 
4
 
 Treg were initially identified as CD4
+
 T cells that also highly express CD25, the 
alpha chain of the IL-2 receptor.
2
  These surface markers were found to be specific for 




 T cells were 
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determined to be non-specific for human Treg. CD25 is an early marker of T cell 
activation and up to 30% of CD4
+
 cells in the peripheral blood may express low levels of 
CD25 due to continuous antigenic exposure.
5
  Treg were determined to have higher 
CD25 expression as compared to the low expression of CD25 by transiently activated T 
cells but more specific means of Treg detection were needed.
5
 The intracellular 
transcription factor, forkhead box P3 (FoxP3), was identified as a highly specific marker 
of murine Treg and subsequent work supports that FoxP3 is up regulated in human Treg 
as well.
6,7






 Treg constitute about 5-10% of CD4
+
 T cells in the 
peripheral blood of humans and defining characteristics include existence in an anergic 
state and active inhibition of effectors T cells, dendritic cells, NK cells, and B cells via 
cell-to-cell contact and in a dose dependent manner.
8
















Regulatory T cells and Cancer 
 There is great interest in the role that Treg may play in inhibition of anti-tumor 
immune responses.  Treg exert their immunosuppressive effects primarily through the 
secretion of transforming growth factor- β (TGF-β) and interleukin-10 (IL-10). There are 
several inhibitory mechanisms of IL-10, including inhibition of cytotoxic T cell 
responses, down regulation of activated macrophages, and inhibition of dendritic cells; 
TGF-β inhibits CD8
+
 T cell cytotoxic activity as well as suppresses NK cell anti-tumor 
responses.
10-14
 This suppression of both the innate and adaptive immune responses 
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against tumor cells likely impacts the response to treatment and overall prognosis of 
cancer patients. 
 Treg are increased in the peripheral blood and lymph nodes and within tumors for 
a number of human malignancies, including ovarian carcinoma, gastric and esophageal 
cancer, pancreatic and breast cancer, colorectal cancer, melanoma, and hepatocellular 
carcinoma.
15-20
 More importantly, increased numbers of Treg have been negatively 
associated with prognosis for several of these malignancies. This was first identified in 
ovarian carcinoma where increased Treg infiltration within the tumor is associated with 
decreased survival.
21
 Since that time, similar inverse correlations with tumor recurrence 
and/or patient survival have been identified for Treg in the tumor of non-small cell lung 
cancer (NSCLC), blood of patients with hepatocellular carcinoma, and the in tumor 
draining lymph nodes in breast cancer patients.
15,22,23
 Increases in Treg are often 
associated with changes in other effector T cell populations, namely decreases in CD8
+
 T 
cells; alterations in these populations may also be expressed as ratios of CD8
+
 T cells to 
Treg. Increased ratios of intratumoral CD8/Treg have similarly been associated with 
improved patient outcome for several malignancies.
24,25
 While increased numbers of Treg 
are most frequently negative predictors of outcome in human cancer, this relationship 
does not always hold true.  There are several studies which have shown no association 
between Treg and patient outcome, as well as several where there is a positive correlation 
between Treg and patient survival.
26-28
 
Evidence that increased numbers of Treg may play a role in patient outcome in 
human malignancies has led to the investigation of the role of Treg in canine cancer. 
Until recently, antibodies against canine CD25 were not available and therefore, canine 
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Treg have been identified in normal and cancer-bearing dogs, and dogs with melanoma, 
osteosarcoma (OSA), and lymphoma have a significantly greater numbers of Treg in 
circulation than healthy dogs.
29-32




 cells have 
increased expression of IL-10 and TGF-β mRNA, supporting their immunosuppressive 
function.
29
 Studies examining the prognostic implication of Treg are limited but dogs 
with OSA that have a high pre-treatment CD8/Treg ratio in the blood have a longer 
survival than dogs with a low CD8/Treg ratio.
31
 Distribution of Treg and effector T cells 
in blood, lymph nodes, and tumors should be investigated further for different types of 
canine cancer and may give further insight into alterations of the immune system that 
occur with neoplastic processes.  
As Treg generally correlate with poor patient survival, the next question becomes 
whether selective depletion of Treg may improve response to therapy and patient 
outcome. Some of the approaches that have been investigated to date include use of 
deniluekin diftitox, anti-CD25 antibody (PC61), and low dose chemotherapy. Denileukin 
diftitox is an IL-2-diptheria toxin fusion protein that binds to cells that express CD25 and 
is subsequently taken up into the cell where it inhibits protein synthesis resulting in cell 
death.
33
 Anti-CD25 antibody specifically binds to the IL-2 receptor alpha chain on T cells 
and has been shown to decrease tumor growth and improve survival in murine models of 
cancer.
34
 Finally, metronomic chemotherapy, defined as the frequent administration of 
low doses of antineoplastic drugs, has been investigated as means to decrease Tregs.  
While it has been utilized most frequently for its antiangiogeneic properties, there is 
accumulating evidence that metronomic chemotherapy also depletes Treg. 
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Metronomic Chemotherapy and Regulatory T cells 
Chemotherapy has traditionally been administered to patients at doses that result 
in direct cytotoxicity to tumor cells; this manner of dosing cytotoxic agents is referred to 
as maximally tolerated dose (MTD) chemotherapy.  MTD chemotherapy inhibits or kills 
rapidly dividing tumor cells, but it also can damage cells that turn over rapidly under 
normal homeostatic conditions resulting in significant adverse effects to the patient.  
Because of normal tissue toxicity, prolonged breaks are needed between doses of 
chemotherapy to allow for the recovery of these tissues, namely the gastrointestinal tract 
and bone marrow. There is some thought that these prolonged breaks may also allow the 




In contrast, metronomic chemotherapy involves the administration of 
chemotherapy drugs at doses much lower than MTD without prolonged breaks between 
treatments and is generally not associated with severe systemic toxicities. Rather than 
causing direct cytotoxicity to tumor cells, metronomic chemotherapy has been 
demonstrated to inhibit tumor angiogenesis.
36
 Angiogenesis is a process critical to tumor 
growth and progression; inhibition of this process has been theorized to improve tumor 
control.
37
 Proposed mechanisms of antiangiogenesis induced by metronomic 
chemotherapy include targeting the drug-sensitive endothelial cell compartment of 
tumors, inhibiting mobilization of proangiogenic circulating endothelial cells from the 






While the antiangiogenic properties of metronomic chemotherapy are well 
studied, there is accumulating evidence that the antitumor effects of metronomic 
chemotherapy may be also due to immunomodulation in part through Treg depletion. The 
association of Treg depletion and improved tumor immunogenicity in a murine model 
was first reported in 1999 by Shimizu et al.
41
  Subsequent work in mice has demonstrated 
that metronomic dosing of cyclophosphamide (CYC), an alkylating nitrogen mustard 
compound, not only decreases numbers of Treg but also inhibits their immunosuppressive 
function.
42,43
 Studies in human malignancies are limited but support earlier findings that 
metronomic CYC decreases numbers of Treg and restores effector T cell function.
44,45
 
Delay of tumor growth and tumor regression secondary to metronomic CYC 
administration has been demonstrated in a number of rodent xenograft models.
46,47
 
Additionally, metronomic CYC may improve the efficacy of other treatment modalities, 
such as other antiangiogenic drugs, MTD chemotherapy, and immunotherapy.
48-51
 Studies 
examining the effects metronomic chemotherapy in human cancers are limited to several 
small studies.  In these studies, metronomic chemotherapy is generally combined with 
other agents such as steroids, non-steroidal anti-inflammatory drugs (NSAID), MTD 
chemotherapy, and/or immunotherapy; there is some preliminary evidence that these 
combination protocols may provide some clinical benefit to patients.
52-56
 
Although metronomic chemotherapy protocols are widely used in veterinary 
oncology, studies examining their efficacy against canine cancer are limited.  CYC is 
frequently used in these protocols primarily due to its aforementioned antiangiogenic and 
immunomodulatory properties. CYC has the advantage of oral administration and is 
relatively inexpensive. Most protocols consist of drug combinations, and have included a 
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combination of CYC with a NSAID, or alternating with etoposide.
57,58
  While 
metronomic chemotherapy may have antitumor effects against canine splenic 
hemangiosarcoma and soft tissue sarcoma, the use of combination therapy precludes 
determination of the clinical effect of each drug. Additionally, CYC doses have been 
empirically selected and doses used ranged from 10 to 25 mg/m
2
/day. Finally, the 
underlying mechanisms of tumor inhibition have not been investigated. Clearly, 
additional research is required to determine the mechanisms of action of metronomic 
chemotherapy and to determine an optimal dose to be used to treat dogs with cancer. 
 
Concluding remarks 
To address some of these gaps in our understanding of the role of Treg in canine 
cancer, the following chapters describe research performed to further elucidate the 
prognostic role of Treg in canine cancer as well as examine the effect of metronomic 
dosing of CYC on Treg.  The second chapter evaluates distribution of Treg in blood, 
lymph nodes, and tumors of OSA-bearing dogs and compares the results to Treg in 
comparable tissues of healthy, control dogs.  Additionally, numbers of Treg in these 
tissue compartments were examined to determine association with disease-free interval or 
survival for dogs with OSA.  The third chapter investigates the effect of metronomic 
CYC therapy on circulating Treg in dogs with soft tissue sarcoma (STS). Two biomarkers 
of antiangiogenic activity, tumor microvessel density (MVD) and circulating endothelial 
cells, were also examined to determine if metronomic CYC inhibits angiogenesis in 
canine STS. Together, this research will provide further information regarding alterations 
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of Treg populations in cancer bearing dogs and assess whether metronomic dosing of 
CYC decreases Treg. The information gained here will ultimately guide future studies to 
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 effector T 
cells and regulatory T cells (Treg), is frequently altered in advanced cancers. These 





 T cells as well increases in Treg.
1-3
 Treg are a distinct subset of CD4
+
 T 
lymphocytes that function normally to prevent harmful autoimmune responses and have 
been shown in mouse models to impair anti-tumor immune responses.
4,5
 Treg likely also 
impair anti-tumor immunity in humans, as they are frequently present in high numbers in 
human cancer patients and have been associated with a less favorable outcome for certain 
malignancies.
3,6-8
   
There is limited information available regarding the role of Treg in cancer of 
companion animals. Canine Treg have been identified based on surface expression of 





Treg constitute about 5% of CD4
+
 T cells in healthy dogs.
9,10
 In addition, Treg have been 
tentatively shown to be increased in the peripheral blood of dogs with various types 
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of carcinoma, oral melanoma, and osteosarcoma (OSA) as compared to healthy control 
dogs.
10-12
 There is currently limited information regarding alterations in T cell subsets 
and their association with outcome in dogs with cancer.
11
 
The purpose of this prospective study was to evaluate T cell subpopulations in the 
blood, lymph nodes, and tumor of dogs with OSA and investigate their association with 
clinical outcome. We hypothesized that dogs with OSA would have increased numbers of 
Treg in their blood and tumor draining lymph nodes as compared to blood and lymph 
nodes of healthy control dogs.  We also hypothesized that OSA dogs with higher 
numbers of circulating Treg would have a shorter disease free interval (DFI) and overall 
survival (OS) as compared to dogs with lower numbers of circulating Treg. 
 
MATERIALS AND METHODS 
Inclusion Criteria 
 Dogs presenting to the Colorado State University Veterinary Teaching Hospital 
(CSU-VTH) with histopathologically confirmed OSA of the appendicular skeleton were 
eligible for enrollment in this prospective clinical trial.  Additionally, dogs with 
radiographic findings consistent with appendicular OSA but without biopsy confirmation 
were also eligible for enrollment.  Exclusion criteria included presence of pulmonary 
metastasis at the time of diagnosis or treatment with chemotherapy or radiation therapy 
within three weeks of study enrollment. Glucocorticoids and non-steroidal anti-
inflammatory drugs were allowable prior to enrollment and throughout the duration of the 
study. Dogs underwent amputation of the affected limb followed by chemotherapy 
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consisting of either single agent carboplatin, alternating carboplatin and doxorubicin, or 
single agent doxorubicin. Dogs receiving single agent carboplatin chemotherapy were 
treated at a dosage of 300 mg/m
2
 intravenously (IV) once every three weeks for a total of 
four treatments.  Dogs that received alternating treatments of doxorubicin and carboplatin 
received chemotherapy once every three weeks for a total of six treatments; three doses 
of doxorubicin were administered at a dosage of 30 mg/m
2
 IV and three doses of 
carboplatin were administered at dosage of 300 mg/m
2
 IV. Dogs receiving single agent 
doxorubicin were treated at a dosage of 30 mg/m
2
 IV once every three weeks for a total 
of five treatments. This study was approved by the Institutional Animal Care and Use 
Committee at Colorado State University, and signed informed consent was obtained from 
all owners prior to study entry. 
 
Sample Collection 
 For analysis of Treg and effector T cells in normal dogs, blood samples were 
collected from 22 healthy control dogs.  For dogs with OSA, whole blood was collected 
prior to surgery and again 18 to 24 hours after amputation.  During surgery, a small tissue 
sample was obtained of the tumor and of the regional lymph node.  Aspiration of a non-
tumor draining lymph node was also performed prior to surgery and again 18 to 24 hours 
post-operatively. Collection of whole blood and an aspirate of a non-tumor draining 
lymph node were also collected one week after the first treatment with chemotherapy. 
Additionally, the pre-treatment T cell populations in the blood and lymph nodes of dogs 
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with osteosarcoma were compared to a T cells in the blood and lymph nodes of a 
population of age-matched healthy control dogs. 
 
Sample Preparation 
 For evaluation of circulating Treg, PBMC were obtained from blood samples 
collected in EDTA tubes after lysis of red blood cells. PBMC were added at a 
concentration of approximately 1 x 10
6
 cells per well in 96-well round bottom plates and 
then immunostained for surface expression of CD4 and CD8 using FITC-conjugated anti-
canine CD4 mAB (clone YKIX302.9, AbD Serotec, Raleigh, NC) and Alexa 647-
conjugated anti-canine CD8 mAB (clone YCATE55.9, AbD Serotec) following the 
method described previously.
13
  Immunostaining for FoxP3 expression was conducted as 
previously described.
9
   Briefly, after washing to remove unbound surface antibodies, 
intracellular detection of FoxP3 was performed using a cross-reactive, PE-conjugated 
murine FoxP3 antibody (clone FJK-16s, Mouse FoxP3 staining kit, eBioscience, San 
Diego, CA). A directly conjugated rat IgG2A antibody was used as the isotype control.  
Lymph node aspirates were processed prior to immunostaining by washing with 
Hank’s balanced salt solution containing 2% fetal bovine serum through a 70 µm strainer.  
Tumor tissues were incubated in one to two milliliters of a 5 mg/ml collagenase solution 
containing collagenase (C-9891, Sigma, St. Louis, Missouri), DNase I (D4263, Sigma), 
trypsin inhibitor (T6522, Sigma), and minimal essential medium (11095, Invitrogen, 
Carlsbad, California) prior to being washed through a 70 µm strainer.  The cells collected 
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from the lymph nodes and tumor were then added to 96-well plates and immunostained 
as described above. 
 
Flow Cytometric Analysis 
 Flow cytometry was performed using a CyAn ADP flow cytometer (Dako-
cytomation, Fort Collins, CO) and Summit software (Dako-cytomation) for data analysis.  
Analysis gates were set on the live lymphocyte population based on typical forward and 
side scatter characteristics.
14





 cells within the CD4
+










 T cells in peripheral blood were calculated based on the total lymphocyte count 
determined from a CBC run on an automated cell counter. 
 
Statistical Analysis 
Mean percentages and numbers of Treg, effector T cells, and the mean CD8/Treg 
ratio were compared between normal and OSA-bearing dogs by an unpaired, two-tailed t-
test. Mean percentages and numbers of Treg, T effector cells, and the mean CD8/Treg 
ratio pre- and post-operatively as well as pre- and post-chemotherapy were compared by 
a paired, two-tailed t-test. Comparisons between multiple groups were done by one-way 
ANOVA with Tukey’s multiple means comparison. Repeated measures ANOVA was 
used to further asses changes over time. Patients were censored from disease-free interval 
(DFI) and overall survival (OS) analysis if they were lost to follow-up; all dogs that died 
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or were euthanized were presumed to be dead of disease. DFI was defined as the time 
from amputation until the development of metastasis and ST was defined as the time 
from amputation until death. Median DFI and ST were calculated by the Kaplan-Meier 
product limit method and compared between groups by log rank analysis. Variables 
assessed for value as predictors of outcome included percentages and absolute numbers 
of Treg, CD4
+
 T cells and CD8
+ 
T cells, the CD8/Treg ratio, and type of postoperative 
chemotherapy used. Statistical calculations were performed using a commercial software 
program (GraphPad Prism version 5 for Windows, GraphPad Software, La Jolla, CA). A  
P value of <0.05 was considered statistically significant for all analyses.  
 
RESULTS 
 Nineteen dogs with histopathologically confirmed or clinically suspected OSA of 
the appendicular skeleton were enrolled in this clinical trial; all underwent amputation of 
the affected limb. Fourteen dogs fulfilled the study criteria. Of the remaining five dogs, 
two did not undergo treatment with adjuvant chemotherapy, two were lost to follow-up 
shortly after amputation, and one dog did not have histopathologic evidence of OSA. For 
the dogs that underwent treatment with adjuvant chemotherapy, six dogs received four 
cycles of carboplatin, seven dogs were treated with three cycles each of alternating 
carboplatin and doxorubicin for seven dogs, and one dog received five doses of 
doxorubicin.  
Analysis of the pre-treatment T cell populations in blood and lymph nodes of the 
18 dogs with histopathologically confirmed OSA were compared with 28 control dogs.  
The average age of dogs with OSA was 8.5 years (range, 5 to 12 years) and the average 
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of the control dogs was 7.8 years (range, 2 to 14 years); this difference was not 
statistically different (P = 0.32). 
 
Treg Are Not Increased in Blood or Lymph Nodes of Dogs with OSA 
 Blood and lymph node samples were collected from control dogs and dogs with 




 T cells and Treg.  




 T cells in the blood were determined by 
the percentage of each cell type multiplied by the total number of lymphocytes as 
determined from the patient’s complete blood count. Representative dot plots for Treg 
analysis from the blood of a healthy dog and a dog with OSA are shown in Figure 2.1. 





cells within the overall CD4
+
 T cell population. 
Dogs with OSA did not have significantly different percentages or absolute 
numbers of Treg in the blood as compared to healthy control dogs (Figure 2.2). The mean 
percentage of Treg in the blood of dogs with OSA was 5.51 (± 2.13)% versus 4.46 (± 
1.41)% in the blood of control dogs (P = 0.052).  The mean absolute number of Treg in 
the blood was also not significantly different between dogs with OSA and control dogs 
(74.5 ± 43.4 cells/µL versus 74.6 ± 46.6 cells/µL, P = 0.99). 
To assess whether Treg percentages were different in lymph nodes of normal dogs 
as compared to healthy control dogs, lymph node samples were obtained by fine needle 
aspiration of any assessable lymph node in control dogs as well as lymph nodes distant 




Figure 2.1: Flow cytometric analysis of regulatory T cells (Treg) in blood of dogs. Peripheral blood 
mononuclear cells from a healthy dog (A) and a dog with osteosarcoma (B) were immunostained for 
expression of CD4 and FoxP3, as described in “Materials and Methods.” (C) Staining of blood form the 
same dog as in (A) with an irrelevant iso-type control for specificity of FoxP3 staining. The percentages of 
































Figure 2.2: Treg in blood are not significantly different in dogs with osteosarcoma (OSA) compared 
to healthy control dogs. Blood samples of control dogs (n = 28) and dogs with OSA (n = 18) were 
analyzed with flow cytometry to determine the percentage and absolute numbers of Treg, as described in 
“Materials and Methods.” The mean percentage (long horizontal line) of Treg in the blood of normal dogs 
and dogs with OSA was plotted in (A) and the mean of the absolute numbers (long horizontal line) was 
plotted in (B). Error bars show SD. Neither the percentage nor the absolute number of Treg was 





by flow cytometric analysis.  The regional, tumor-draining lymph node was also sampled 
from dogs with OSA at the time of amputation to assess whether Treg were increased in 
the regional lymph node as compared to a lymph node distant to the tumor site.  Treg 
percentages were similar in the regional lymph node and distant lymph nodes and also 
similar to Treg percentages found in healthy dogs (Figure 2.3).  Thirteen of the 18 dogs 
with OSA had histopathologic evaluation of the regional lymph node at the time of 












Figure 2.3: Percentages of regulatory T cells (Treg) in regional and distant lymph nodes are similar 
to those of healthy control dogs. The percentage of Treg was determined in lymph node (LN) aspirates 
from normal dogs (n = 8) and in LN distant from the primary tumor in dogs with OSA (n = 10).  A portion 
of the LN nearest the tumor (regional LN) was sampled at the time of amputation for dogs with OSA (n = 
16).  The mean percentages of Treg (long horizontal line) were compared between the control dogs and 
regional and distant LN of dogs with OSA.  Error bars show SD.  No significant difference was detected 
between the three populations (P = 0.46). 
 
 
The Distribution of T cell Subsets in the Peripheral Blood are Altered in 
Dogs with OSA 
To assess whether dogs with OSA had changes in the distribution of their T cell 







 T cells in the blood of OSA-bearing dogs were compared to healthy control dogs. 
The percentage of CD4
+
 T cells was increased in dogs with OSA as compared to the 
control dogs but absolute numbers of CD4
+
 cells were not significantly different (Table 
2.1).  However, both the percentage and absolute number of CD8
+
 T cells were 
significantly decreased in dogs with OSA as compared to control dogs (Table 2.1).  
Despite the decreases the CD8
+
 T cells in dogs with OSA, there was no significant 
difference in the total lymphocyte count between the two groups. 
Table 2.1: Percentages of T effector cells in blood, lymph nodes, and tumor in healthy control dogs 
compared to dogs with OSA. DLN, distant lymph node; RLN, regional lymph node. 
Parameter Site 
Control 
Mean (± SD) 
OSA 
Mean (± SD) P-value 
Total lymphocytes (cells/µL) Blood 1,645 (807) 1,336 (558) 0.162 
% CD4
+
 T cells Blood 47.6 (10.4) 60.9 (14.9) <0.001 
Total # CD4+ T cells (cells/µL) Blood 752 (339) 792 (372) 0.708 
% CD8
+
 T cells Blood 22.1 (8.74) 15.1 (8.55) 0.011 
Total # CD8
+
 T cells (cells/µL) Blood 357 (203) 223 (169) 0.025 
% CD4+ T cells DLN 38.9 (9.37) 37.6 (17.9) 0.858 
% CD8+ T cells DLN 13.1 (4.47) 13.8 (10.2) 0.857 
% CD4+ T cells RLN NA 37.4 (13.7)  
% CD8+ T cells RLN NA 10.6 (5.42)  
% CD4+ T cells Tumor NA 21.8 (16.4)  
% CD8+ T cells Tumor NA 9.04 (8.24)  
 
Treg Percentages are Lowest in Peripheral blood in Dogs with OSA 
 To examine the distribution of T lymphocytes subsets in different compartments 




 T cells in regional and 
distant lymph nodes, peripheral blood, and the tumor of dogs with OSA were compared. 
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The mean percentage of Treg in the blood was significantly decreased as compared to the 
mean percentage of Treg in the tumor and regional and distant lymph nodes (P < 0.0001; 
Figure 2.4 C). There was no significant difference in mean percentage of Treg between 
both lymph node sites and the tumor. 
CD4
+
 T cells were found in greatest percentages in the blood as compared to the 
tumor and regional and distant lymph nodes in dogs with OSA. The mean percentage of 
CD4
+
 T cells in the peripheral blood was 60.9 (± 14.9)% as compared to 37.4 (± 13.7)% 
in the regional lymph node, 41.6 (± 15.2)% in the distant lymph node, and 21.8 (± 16.4)% 
in the tumor (P < 0.0001). There was no significant difference in the mean percentages of 
CD8
+










































Figure 2.4: Variation in T lymphocyte subpopulations in blood, regional lymph nodes (RLN), distant 
lymph nodes (DLN), and tumor for dogs with osteosarcoma (OSA). The percentages of CD4+ and CD8+ 
and Treg were determined in blood, tumor, RLN and DLN for the 18 dogs with OSA. The mean 
percentages of Treg (long horizontal line) were compared between the tissue sites by one-way ANOVA and 
Tukey’s multiple comparisons post-test. Error bars show SD. (A) There was a significant increase in the 
percentage of CD4+ T cell in the blood as compared to the RLN, DLN, and tumor (P < 0.0001) but no 
difference was observed in the percentage of CD8+ T cells between the four sites (B).  (C) Treg were 
significantly lower in the blood as compared to the RLN, DLN, and tumor (P < 0.0001). *denotes 
significantly different mean percentage of cells from other tissue sites. 
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Alterations in T cell subsets of peripheral blood and LN post-operatively and after 
chemotherapy 
 To evaluate whether Treg and T effector cells were altered after treatment with 





 T cells in the blood of dogs with OSA were compared to the 
post-operative and one week post-chemotherapy means using repeat measures ANOVA 
and Tukey’s multiple comparisons post-test. While there were no significant differences 
between the mean percentage of pre-treatment, post-operative, and post-chemotherapy 
CD4
+
 T cells, the absolute number of CD4
+
 T cells in the blood was significantly 
decreased after amputation (Table 2.2).  There was no difference in the mean percentage 
of CD8
+
 T cells at any time point, but there was a significant increase in the mean 
absolute number of CD8
+
 T cells between the post-operative time point and one week 
post-chemotherapy. A significant increase in the mean percentage and absolute number 
of Treg occurred between the post-operative and post-chemotherapy time points.  
Additionally, mean percentages of Treg post-chemotherapy were significantly increased 
from pre-treatment percentages. 
There were insufficient distant lymph node aspirates obtained one week after 





and Treg could be compared.  There were no significant differences in the mean 
percentages of any of the T cell subsets pre- and post-operatively in the lymph node 




Table 2.2: Comparison of mean percentages of T effector cells in blood (n = 11) and distant lymph 




Mean (± SD) 
Post-Op 
Mean (± SD) 
Post-Chemo 
Mean (± SD) P-value 





% CD4+ T cells Blood 60.1 (14.3) 54.7 (12.1) 50.1 (15.7) 0.147 
Total # CD4
+
 T cells (cells/µL) Blood 743 (421)* 336 (177)* 636 (220) 0.009 
% CD8+ T cells Blood 15.1 (9.10) 12.3 (11.1) 21.7 (12.7) 0.105 
Total # CD8
+
 T cells (cells/µL) Blood 215 (178) 89.9 (114)* 291 (204)* 0.046 
% Treg Blood 5.55 (2.00)* 5.67 (1.87)
 †
 8.52 (3.40) *
†
 0.016 
Total # Treg (cells/µL) Blood 71.3 (41.9) 38.2 (37.8)* 98.8 (36.9)* 0.019 
% CD4+ T cells DLN 41.6 (15.2) 41.6 (18.2) NA 0.705 
% CD8+ T cells DLN 11.2 (9.18) 7.76 (5.15) NA 0.090 
% Treg DLN 16.9 (8.25) 167.0 (8.70) NA 0.937 
Symbols (*,†) indicate means that significantly different based on Tukey’s multiple comparison test 
 
Patient Outcome 
 For the 14 dogs that received adjuvant chemotherapy and outcome was known, 
the median disease free interval (DFI) was 253 days (range, 39 to 1252 days) and median 
overall survival (OS) was 348 day (range, 72 to 1252 days).  There was no significant 
difference in either DFI or OS between dogs that received doxorubicin based 
chemotherapy and dogs that received single-agent carboplatin chemotherapy (P = 0.91 
and 0.46, respectively). 
 Both elevated numbers of Treg and low CD8/Treg ratios have been found to be 
negatively associated with prognosis in human cancer patients.
6,15,16
 For this reason, the 
relationship of T cell subpopulations as well as CD8/Treg ratio to DFI and OS were 
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investigated. The median percentage of Treg and the mean CD8/Treg ratio were 
calculated for blood, regional lymph node, and tumor.  Additionally, the median absolute 
number of Treg was calculated for the blood as described previously in this section. 
Kaplan-Meier product limit analysis for DFI and OS were then performed by assigning 
outcome based on whether dogs were above or below the Treg and CD8/Treg ratio 
median values for each tissue compartment. There was no significant difference in 
outcome based percent Treg, absolute number of Treg, or CD8/Treg ratio in the blood or 
regional lymph node.  However, dogs with high CD8/Treg ratios in the tumor had a 
statistically increased DFI of 822 days as compared to dogs with low CD8/Treg ratios 
with a DFI of 205 days (P = 0.04).  The median OS was not reached for dogs with a high 
tumor CD8/Treg ratio compared to dogs with a low CD8/Treg ratio which had a median 
OS of 205 days (P = 0.02). 





































Figure 2.5: High CD8/regulatory T cell (Treg) ratio in the tumor is correlated with prolonged disease 
free interval (DFI) and overall survival (OS) in dogs with osteosarcoma (OSA). Kaplan-Meier graph 
depicting DFI (A) and OS (B) in dogs with OSA with a tumor CD8/Treg ratio equal to or higher (n = 6) or 








 Contrary to our hypothesis, Treg were not significantly increased in dogs with 
OSA as compared to healthy control dogs.  This finding is in contrast to earlier work 
reported by our group where circulating Treg were increased in dogs with OSA but is 
supported by a recent study performed by Rissetto et al where dogs with OSA did not 
have increased Treg as compared to normal dogs.
9-11,17
 One potential explanation for this  
discrepancy is the possibility that circulating Treg do not play a significant role in 
progression of OSA. The lack of published human studies prevents direct comparison 
with our data, but percentages of Treg are similar to those of other bone tumors in people 
such as non-metastatic Ewing sarcoma.
18
 Interestingly, in patients with non-metastatic 
Ewing sarcoma Treg percentages were not elevated as compared to percentages observed 
in healthy individuals but Treg were significantly increased in the bone marrow of 
patients with metastatic disease.
18
  While Treg have been shown to be increased in dogs 
with metastatic tumors, OSA has not been specifically investigated.
19 
 
Similar Treg populations in control and OSA dogs may also be due to 
concomitant medications the dogs received while on study. OSA causes significant bone 
pain necessitating treatment with oral pain medications and non-steroidal anti-
inflammatory drugs (NSAID) are most commonly used.  NSAID mitigate inflammation 
and associated pain through inhibition of a key enzyme in the arachadonic acid pathway, 
cyclooxygenase (COX), to decrease production of prostaglandin E2 (PGE2).
20
 COX-
inhibitors have been shown to decrease the percentage and function of Treg in a non-
small cell lung cancer model in mice.
21
 The isoform COX-2 has been found to be up 
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regulated in canine OSA; additionally, several human malignancies show increased 
tumoral COX-2 expression which correlates with increased Treg numbers.
21-23
 In this 
study, 15 of the 18 dogs with OSA were treated with a NSAID prior to and concurrent 
with this study. It is possible that pre-treatment with a NSAID decreased Treg in OSA-
bearing dogs prior to enrollment into this trial resulting in Treg numbers similar to the 
normal dog population. To date, there have been no studies performed evaluating the 
effect of NSAID on canine Treg. 
 Dogs with OSA had significantly decreased pre-treatment percentage and 
absolute number of CD8
+
 T cells as compared to healthy dogs in this study. This finding 
is supported by previous work which also shows that dogs with OSA have decreased 
numbers of CD8
+
 T cells two weeks post-amputation, prior to initiation of 
chemotherapy.
13
  In contrast to the same study, which found that CD4
+
 T cells were also 
decreased in dogs with OSA prior to starting chemotherapy, we found that dogs with 
OSA had an increased percentage, but not total number of CD4
+
 T cells.  This is likely 
due to the artificial inflation of CD4
+
 T cell percentage secondary to the decrease in CD8
+
 
T cells as the absolute number of CD4
+
 T cells was not altered. This difference in the 
percentage of peripheral CD4+ T cells is not likely clinically relevant as absolute 
numbers of CD4+ cells were similar between control and OSA-bearing dogs. Despite 
significant decreases in the percentage and absolute number of CD8+ T cells and 
increases in the percentage of CD4+ T cells, mean total lymphocytes counts were within 
normal limits for dogs with OSA and not significantly different from mean lymphocyte 
counts of healthy control dogs.   
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Distributions of T lymphocyte subsets are frequently altered in the regional (tumor-
draining) lymph nodes of human malignancies as compared to lymph nodes distant from 
the tumor.
24-26  The distribution of Treg and CD4+ and CD8+ T cells was not significantly 
different in either the regional or distant lymph node of dogs with OSA as compared 
healthy control dogs.  There are several possible explanations for this finding.  It is 
possible that the lymph node sampled was not truly the draining lymph node as these 
could be difficult to identify and sample for dogs with proximal bone lesions. Another 
possible explanation is Treg accumulation in regional lymph nodes is not an important 
aspect of OSA progression as this tumor generally metastasizes hematogenously. OSA 
does occasionally metastasize to regional lymph nodes and this was documented in 2 of 
the 13 dogs for which histopathologic data was available for analysis in this study.  Both 
of these dogs had percentages of Treg in the metastatic lymph node that exceeded the 
mean percentage of Treg in regional lymph nodes of dogs with OSA but this sample size 
is too small to subject to any meaningful statistical analysis. 
Changes in T cell subsets were identified both post-operatively and one week after 
the first dose of chemotherapy.  A significant decrease in the total lymphocyte count and 
number of CD4
+
 T cells in the blood was observed after surgery.  Post-operative 
lymphopenia is well documented in people and a study in pediatric patients found that 
total lymphocytes as well as CD4
+
 T cells were significantly decreased 6 to 48 hours 
post-operatively.
27
 It is possible that changes in total lymphocytes and CD4
+
 T cell 
numbers in our study are secondary to surgical/anesthetic stress. CD8
+
 T cells and Treg 
in the blood were found to be increased one week post-chemotherapy compared to the 
post-operative period. Information regarding changes in T cell population after 
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maximally tolerated dose chemotherapy is lacking, but there is some evidence that  
increases in CD8
+
 T cell may be observed in tumor draining lymph nodes after 
combination chemoradiation.
28
 Increases in Treg are often associated with advanced 
stage disease in humans but there is no evidence that the dogs in our study had early 
disease progression based on routine radiographic evaluation of the thorax. More work is 
need to determine if these increases are simply associated with a “rebound” of the bone 
marrow after treatment with myelosuppressive drugs. 
Treg numbers or percentages in the blood, lymph node, or tumor were not associated 
with either DFI or OS, but the intratumoral (IT) CD8/Treg ratio was positively correlated 
to both DFI and OS. This finding is similar to human colorectal cancer where a high IT 





 The positive association between high IT 
CD8/Treg ratio and survival has also been demonstrated for ovarian and gastric 
carcinoma.
15,30
 The alterations of the tumor infiltrating lymphocytes (TIIL) may be a 
reflection of the patients’ immune response to the tumor.  
In conclusion, we found that an increased pre-treatment intratumoral CD8/Treg ratio 
was associated with prolonged DFI and OS for dogs with OSA. Circulating Treg in dogs 
with OSA were not significantly increased compared to healthy dogs in this study.  These 
findings suggest that increased intratumoral Treg may be associated with more aggressive 
or advanced stage OSA but these intratumoral increases are not reflected in the peripheral 
blood.  Because of the small sample size, results of this study should be considered 
preliminary. The effects of COX-2 inhibitors on canine Treg should be further 
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investigated before additional work is performed on OSA-bearing dogs to better 
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Low Dose Cyclophosphamide Selectively Decreases Regulatory T Cells and Inhibits 
Angiogenesis in Dogs with Soft Tissue Sarcoma 
 
INTRODUCTION 
Metronomic chemotherapy is defined as the continuous administration of 
chemotherapy drugs at doses that are significantly lower than conventional maximally 
tolerated dose (MTD) therapy.
1
  In contrast to the direct cytotoxic effects of MTD 
chemotherapy, metronomic drug delivery inhibits tumor angiogenesis, a process critical 
for tumor development and progression.
2
  There are several proposed mechanisms for 
these effects, including targeting of the drug-sensitive endothelial cell compartment of 
tumors, inhibiting mobilization of proangiogenic circulating endothelial cells from the 




In addition to antiangiogenic properties, there is accumulating evidence that 
metronomic chemotherapy modulates the immune system of tumor bearing patients 
through inhibitory effects on regulatory T cells (Treg).  Treg, a subset of CD4
+
 
lymphocytes that normally function to prevent autoimmunity, have recently been shown 
to inhibit antitumor immune responses.
6-8
  Treg are frequently present in high numbers in 
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human cancer patients and increased numbers of Treg may be associated with a less 
favorable outcome for certain malignancies.
9-12
  Treg are also increased in the peripheral 
blood of dogs with various types of cancer; however, the prognostic significance of this 
finding is unclear.
13-17
  In mice and humans with advanced cancer, the administration of 
metronomic doses of cyclophosphamide (CYC) selectively decreases circulating Treg 
numbers and inhibits their function.
18-20
  The effects of low dose CYC on canine Treg 
have not been previously reported. 
Despite its frequent use in veterinary patients, metronomic chemotherapy has not 
been systematically evaluated and dosing schedules and drug combinations have been 
selected empirically.
21,22
 Metronomic chemotherapy appears well tolerated in dogs and 
may have antitumor effects, but studies to identify optimal dosing, mechanisms of action, 
and biomarkers of drug activity are lacking. There are several challenges in designing 
effective metronomic chemotherapy protocols. First, most protocols tend to utilize a 
combination of drugs, each with differing mechanisms of action. The efficacy and 
therefore validity of using these drugs can only be determined once single drug effects 
are known; such experiments have not yet been performed.  Secondly, dose optimization 
has been difficult to establish since low dose protocols are not defined by dose limiting 
toxicities (DLT) in the same manner as MTD chemotherapy.  In addition, therapies that 
target tumor vasculature or a patient’s immune system are unlikely to demonstrate a 
clinical benefit as quickly as high-dose, cytotoxic chemotherapy.  Therefore, standard 
criteria for monitoring antitumor response may be inadequate for assessing efficacy of 
antiangiogenic or immune-modulating therapies.
23
  Finally, clinically applicable 
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biomarkers of tumor response have not been identified, limiting the use of metronomic 
protocols as adjunctive therapies.  
 To address some of these challenges, we first performed a pilot study to evaluate 
whether low dose CYC administered at 10 mg/m
2
/day altered Treg numbers or 
percentages in dogs with various types of cancer.  We then performed a prospective 
clinical trial to evaluate the effects of low dose CYC on Treg numbers and percentages in 
circulation, tumor draining lymph nodes (TDLN), and tumor. To assess whether 
metronomic CYC has antiangiogenic activity in dogs, tumor microvessel density (MVD) 
and circulating endothelial cells (CEC) were evaluated as well.   Our specific goal was to 
determine the dosage of CYC required to decrease Treg and inhibit tumor angiogenesis in 
dogs with soft tissue sarcoma (STS). 
 
MATERIALS AND METHODS 
Pilot Study 
 Dogs presenting to the Colorado State University Veterinary Teaching Hospital 
(CSU-VTH) with histologically confirmed cancer were eligible for inclusion in this pilot 
study. Patients could either have gross or mircoscopic disease and metastatic cancer was 
allowable.  All patients were required to have a Veterinary Co-Operative Oncology 
Group (VCOG) performance status of 0 or 1 (0, normal activity; 1, restricted activity 
(decreased activity from predisease status); 2, compromised (ambulatory only for vital 
activities, consistently defecates and urinates in acceptable areas), 3, disabled (dog needs 
to be force-fed, is unable to confine urination and defecation to acceptable areas); 4, 
dead).  Previous therapy was allowable with a three week washout period from 
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chemotherapy or radiation therapy and a three day washout from any non-steroidal anti-
inflammatory drug (NSAID).  Information recorded included age, breed, sex, body 
weight, CBC results, tumor type and whether there was gross or microscopic tumor 
present. This study was approved by the Institutional Animal Care and Use Committee at 
Colorado State University, and signed informed consent was obtained from all owners 
prior to study entry. 
 Patients were administered CYC 10 mg/m
2
/day at home for 28 days.  The initial 
CYC dosage was selected based on previously published clinical studies examining 





  To improve accuracy of drug administration, CYC was compounded 
into 2.5 mg and 5 mg capsules.  A complete blood count and whole blood for collection 
of peripheral blood mononuclear cells (PMBCs) were obtained at days 0, 14, and 28 after 
beginning CYC therapy.  Circulating Treg were quantitated by flow cytometric analysis 
as outlined later in this section. To assess constitutional and gastrointestinal toxicoses, 
clients completed a patient quality of life questionnaire at each visit. 
 
Inclusion Criteria for Prospective Clinical Trial 
 Dogs presenting to the Colorado State University Veterinary Teaching Hospital 
(CSU-VTH) with histologically confirmed grade 1 or 2 STS were eligible for inclusion in 
this prospective clinical trial.  This population was selected with the rationale that optimal 
treatment for low to intermediate grade STS was unlikely to be adversely affected by 
enrollment in a 4 week long study prior to pursuing definitive treatment.   Patients were 
required to have a measurable and biopsy-accessible tumor, no evidence of metastatic 
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disease or significant biochemical or hematological abnormalities.  Patients were also 
required to have a Veterinary Co-Operative Oncology Group (VCOG) performance status 
of 0 or 1. Previous therapy was allowable with a three week washout period from 
chemotherapy or radiation therapy and a three day washout from any non-steroidal anti-
inflammatory drug (NSAID).  Information recorded included age, breed, sex, body 
weight, CBC results, and tumor size, grade, and location. This study was approved by the 
Institutional Animal Care and Use Committee at Colorado State University, and signed 
informed consent was obtained from all owners prior to study entry. 
 
Treatment Protocols and Sample Collection 
 For analysis of Treg and effector T cells in normal dogs, blood samples were 
collected from twenty-one healthy, age-matched dogs.  Dogs with STS were enrolled in 
two cohorts. The first group was treated with CYC at a target dosage of 12.5 mg/m
2
/day 
administered orally at home by the owners for 28 days; the second was treated with oral 
CYC at target dosage of 15.0 mg/m
2
/day.  The initial CYC dosages for this portion of the 
study were selected based on results of the pilot study.  Again, CYC was compounded 
into 2.5 mg and 5 mg capsules to improve accuracy of drug administration 
A complete blood count, whole blood for collection of peripheral blood 
mononuclear cells (PMBCs), aspirates of the TDLN, and tumor biopsies were obtained at 
days 0, 14, and 28 after beginning CYC therapy.  Tumor biopsies were performed using 
local anesthesia and a needle core biopsy instrument in an aseptically prepared site on the 
tumor.  The longest diameter of the tumor was monitored at each time point and tumor 
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response was assessed using Response Evaluation Criteria in Solid Tumours (RECIST).
24
  
Clients completed a patient quality of life questionnaire at each visit. 
 
Sample Preparation 
 For evaluation of circulating Treg, PBMC were obtained from blood samples 
collected in EDTA tubes after lysis of red blood cells. PBMC were added at a 
concentration of approximately 1 x 10
6
 cells per well in 96-well round bottom plates and 
then immunostained for surface expression of CD4 and CD8 using FITC-conjugated anti-
canine CD4 mAB (clone YKIX302.9, AbD Serotec, Raleight, NC) and Alexa 647-
conjugated anti-canine CD8 mAB (clone YCATE55.9, AbD Serotec) following the 
method described previously.
25
  Immunostaining for FoxP3 expression was conducted as 
previously described.
13
   Briefly, after washing to remove unbound surface antibodies, 
intracellular detection of FoxP3 was performed using a cross-reactive, PE-conjugated 
murine FoxP3 antibody (clone FJK-16s, Mouse FoxP3 staining kit, eBioscience, San 
Diego, CA). A directly conjugated rat IgG2A antibody was used as the isotype control.  
Lymph node aspirates were washed with a PBS buffer containing 2% fetal bovine 
serum through a 70 µm strainer prior to immunostaining.  Tumor tissues were incubated 
in a collagenase buffer for 20 minutes before processing through the strainer.  The cells 
collected from the TDLN and tumor were then added to 96-well plates and 
immunostained as described above. 
 To evaluate CEC, PBMC were obtained from blood samples collected in EDTA 
tubes after lysis of red blood cells.  PBMC were added at a concentration of 
approximately 2 x 10
6
 cells per well in 96-well round bottom plates and immunostained 
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for the surface markers CD3, CD45, and CD146 using FITC conjugated mouse anti-
canine CD3 mAB (CA17.2A12, AbD Serotec) and rat anti-canine CD45 mAB (clone 
YKIX716.13, AbD Serotec), and PE conjugated CD146 mAB (clone P1H12, Millipore, 
Billerica, MA).  For isotype staining, CD3-FITC, CD45-FITC, and a mouse IgG1-PE 
negative control (Millipore) were used to determine gating.  Compensation controls were 
created using CD45-biotin and a secondary stain of the nuclear stain (LDS-751, 
Invitrogen) was added to cells. 
 
Flow Cytometric Analysis 
 Flow cytometry was performed using a CyAn ADP flow cytometer (Dako-
cytomation, Fort Collins, CO) and Summit software (Dako-cytomation) for data analysis.  
Analysis gates were set on the live lymphocyte population based on typical forward and 
side scatter characteristics.
26





 cells within the CD4
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 T cells in peripheral blood were calculated based on the total lymphocyte count 








 and one million or more events were run to insure enough events 
for analysis.   
 
Microvessel Density Assessment 
 Biopsy specimens were embedded in Tissue-Tek OCT compound (Ted Pella Inc, 
Redding, CA), snap frozen in liquid nitrogen, and stored at -80

C until processing.  
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Tissues were cyrosectioned to a thickness of 4 m and adhered to positively charged 
glass slides.  Immunohistochemistry was performed using a mouse anti-human CD146 
monoclonal antibody (clone P1H12, Millipore), that cross reacts with dog endothelium 
and has been validated as a measure of tumor of angiogenesis.
27,28
  The slides were fixed 
in acetone for four minutes, allowed to air dry, and blocked with 5% donkey serum 
(Jackson ImmunoResearch Laboratories, Inc, West Grove, PA).  The tissues were then 
incubated with a 1:100 dilution of the primary antibody followed by a 1:400 dilution of 
biotin-conjugated donkey anti-mouse IgG (Millipore). The slides were then incubated 
with strepavidin-HRP (Vector Laboratories, Burlingame, CA), followed by AEC 
substrate (Vector Laboratories), then hematoxylin counterstain.  Normal canine liver and 
spleen were used as positive control tissues.  Positive control samples were processed as 
outlined above and negative control samples were incubated with 1x PBS rather than the 
primary antibody. 
 To quantify tumor MVD, three to five photomicrographs for each time point were 
obtained at 20X magnification using a Zeiss AxioVision microscope and AxioVision 
Software v4.6 (Zeiss, Thornwood, NY).   Computerized determination of the percentage 
of CD146
+
 vessels positive within each 20x field was performed and averaged for each 
time point.  The number of microvessels also included immunopositive endothelial cells 
or endothelial cell clusters regardless of the presence or absence of a lumen.
29,30
  The 
final MVD value for each time point was calculated as the mean (± SD) percentage of 






 Data regarding age and sex for a population of normal and STS bearing dogs were 
compared using an unpaired, two-tailed t-test.  Data regarding age, sex, weight, and 
tumor size of dogs in the two CYC dose cohorts were also compared using an unpaired, 
two-tailed t-test.  Changes in mean percentages and absolute numbers of Treg and MVD 
were compared using paired, one-tailed t-tests.  Hematologic parameters and mean 




 T cells were compared by paired, 
two-tailed t-tests.  Statistical calculations were performed using a commercial software 
program (GraphPad Prism version 5 for Windows, GraphPad Software, La Jolla, CA). A  




 Seven dogs were enrolled in the pilot study from April, 2008 to June, 2008 and 
these dogs received a mean CYC dose of 9.7 mg/m
2
/day (range 8.7 to 11.1 mg/m
2
/day; 
target dose 10.0 mg/m
2
/day). Five dogs were castrated males and two were spayed 
females with an average age of 10.1 years (range 9.0 to 12.0 years).  Five patients had 
measurable tumors and these included pulmonary metastasis of osteosarcoma, thyroid 
carcinoma, oral fibrosarcoma, pulmonary metastasis with an unknown primary tumor, 
and metastatic anal sac adenocarcinoma to the liver.  Two dogs had mircroscopic tumors; 
these included an incompletely excised extraskeletal osteosarcoma and an incompletely 
excised oral amelanotic melanoma. 
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 To determine the effects of metronomic CYC therapy on numbers of Treg in 
circulation, blood samples were collected on days 0, 14, and 28 and changes in the mean 
absolute number and percentage of Treg were analyzed.  There was no significant change 
in the mean percentage or the mean absolute number of Treg over the 28 day period when 
CYC was administered at 10 mg/m
2
/day (Figure 3.1).  Additionally, there were no 




 T cells as 
assessed by flow cytometry and no significant change in total leukocyte, neutrophil, 
lymphocyte, monocyte, or platelet counts as assessed by CBC on days 0, 14, and 28. 
There were no reported adverse events for any of the patients over the study period (data 












































Figure 3.1: Cyclophosphamide (CYC) administered at 10 mg/m
2
/day does not alter percentages or 
absolute numbers of Treg over 28 days. Relative and absolute numbers of regulatory T cells (Treg) in 
peripheral blood of dogs with various tumor types treated with metronomic CYC at a target dose of 10.0 
mg/m2/day (n = 7) are shown.  The mean percentage (long horizontal line) of Treg for day 0, 14, and 28 
was plotted in (A) and the mean of the absolute number (long horizontal line) of Treg day 0, 14, and 28 was 
plotted in (B).  Error bars show SD.  There was no significant decrease in the mean percentage or absolute 








 Eleven dogs were enrolled in this clinical trial; the first five dogs received a mean 
CYC dose of 12.4 mg/m
2
/day (range 11.2 to 13.9 mg/m
2
/day; target dose 12.5 
mg/m
2
/day) and the next six received a mean CYC dose of 15.8 mg/m
2
/day (range 14.0 to 
17.0 mg/m
2
/day; target dose 15.0 mg/m
2
/day).  Five dogs were castrated males and six 
were spayed females with an average age of 9.9 years (range 6.9 to 12.8 years).  There 
was no significant difference in age, sex, or weight between the two groups; similarly 
there was no significant difference in age or sex between the healthy dogs and those with 
STS (data not shown).  Tumor biopsies were performed for all patients prior to 
enrollment: eight patients had grade 1 STS and three had grade 2 STS; 72.7% (8/11) of 
these tumors occurred at or distal to the elbow or stifle.   
 Average tumor maximal diameter was 9.3 cm with a range of 1.9 to 30 cm; there 
was no significant difference in tumor size between the two dose cohorts.  For all dogs in 
the study, maximal tumor diameters remained stable during the treatment period, 
according to RECIST criteria.  Additionally, no adverse events were reported for any of 
the patients over the 28 day study period. 
 
Circulating Treg are Significantly Increased in Dogs with STS 
 Whole blood was collected from control dogs as well as dogs with STS and 




 T cells and 
Treg in peripheral blood as described in Materials and Methods.   Both the percentage 
and absolute number of Treg in peripheral blood were significantly increased in the dogs 
with STS prior to therapy as compared to healthy dogs (Figure 3.2).  The mean 
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percentage of Treg for dogs with STS was 7.6 (± 3.0) % as compared to 4.8 (± 1.3) % for 
the normal dogs (P <0.001).  The mean absolute number of Treg in peripheral blood was 
also increased in dogs with STS (107.8, SD ± 58.2 cells/L) as compared to the normal 





 cells did not differ significantly between the normal and diseased 









































Figure 3.2: Circulating Tregs are increased in dogs with STS as compared to a healthy control 
population. Blood of control dogs (n = 21) and dogs with STS (n = 12) was analyzed by flow cytometry to 
determine the absolute number and percentage of Treg, as described in “Materials and Methods.” The mean 
percentage (long horizontal line) of Treg in the blood of normal dogs and dogs with STS was plotted in (A) 
and the mean of the absolute number (long horizontal line) of Treg was plotted in (B). Error bars show SD.  
Both the percentage and the absolute number of Treg were significantly increased (P < 0.001) in dogs with 
STS compared with healthy control dogs as assessed by unpaired, two-tailed t-test. 
 
TDLN samples were not obtained in sufficient number for statistical evaluation in 
this study due to the technical difficulty of aspirating normal canine lymph nodes.  
Additionally, insufficient numbers of tumor biopsies were obtained for intratumoral Treg 
assessement.  Due to the sampling challenges encountered, the effect of low-dose CYC 






Low Dose CYC Decreases Treg Numbers in Dogs with STS 
 To determine the effects of metronomic CYC therapy on numbers of Treg in 
circulation, blood samples were collected on days 0, 14, and 28 after beginning oral CYC 
and changes in the mean absolute number and percentage of Treg were analyzed at each 
time point for the two groups of dogs.  For dogs with STS receiving CYC at a target 
dosage of 12.5 mg/m
2
/day, there was no significant change in the mean percentage of 
Treg over the 28 day period (Figure 3.3A).  A significant decrease in the mean absolute 
number of Treg was seen, however, from day 0 to 28 (P = 0.001; Fig 3.3B).  The mean 
absolute number of pretreatment Treg was 78.9 cells/L (± 43.1) which decreased to 54.1 
cells/L (± 43.7) after 28 days of CYC therapy.  No significant change in the absolute 


















































Figure 3.3: Absolute numbers of circulating regulatory T cells (Treg) are decreased between day 0 
and 28. Relative and absolute numbers of Treg in peripheral blood of dogs with soft tissue sarcoma (STS) 
treated with metronomic cyclophosphamide (CYC) at a target dose of 12.5 mg/m2/day (n = 5).  The mean 
percentage (long horizontal line) of Treg for day 0, 14, and 28 was plotted in (A) and the mean of the 
absolute number (long horizontal line) of Treg day 0, 14, and 28 was plotted in (B).  Error bars show SD.  
There was no significant decrease in the mean percentage of Treg between day 0 and 14, day 0 and 28, or 
day 14 and 28 as assessed by paired, one-tailed t-test.  There was no significant decrease in the mean 
absolute number of Treg from day 0 to 14 or day 14 to 28.  A decrease in the mean absolute number of 




 Dogs receiving CYC at a target dosage of 15.0 mg/m
2
/day had significant 
decreases in both the absolute number and percentage of Treg in the peripheral blood 
during the 28 day study period (Figure 3).  For this group of patients, a significant 
decrease in the mean percentage and mean absolute number of Treg occurred between 
days 14 and day 28 (7.4 ± 3.1 versus 5.8 ± 3.5%; P = 0.035 and 121.1 ± 64.1 versus 55.7 
















































p = 0.035 p = 0.049
 
Figure 3.4: Metronomic cyclophosphamide (CYC) at a target dose of 15.0 mg/m2/day (n = 6) 
decreases Treg in peripheral blood between days 14 and 28.  The mean percentage (long horizontal line) 
of Treg for day 0, 14, and 28 was plotted in (A) and the mean of the absolute number (long horizontal line) 
of Treg day 0, 14, and 28 was plotted in (B).  Error bars show SD.  A significant decrease in the mean 
percentage of Treg and the mean absolute number of Treg was observed between day 14 and 28 (P = 0.035 
and P = 0.049, respectively) as assessed by paired, one-tailed t-test. 
 
Low Dose CYC Mediates Selective Decreases in Treg 
 To determine the effects of low dose CYC on leukocyte numbers, a complete 
blood count was performed at each study time point for all patients.  There were no 
significant changes in the total numbers of neutrophils, lymphocytes, monocytes, or 
platelets in dogs with STS receiving CYC at 12.5 mg/m
2
/day or 15.0 mg/m
2
/day.  To 








populations were also evaluated.  Despite the decrease of Treg at the higher dosage of 





 lymphocytes during the course of the clinical trial, suggesting that the effects of 
CYC were selective for the Treg subset of T-lymphocytes (Table 3.1).   
 




 lymphocyte subpopulations are not significantly altered in dogs with soft 




 cohort  




 cohort  
(mean ± SD) 
P value Day 0 Day 28 Day 0 Day 28 
% CD4
+
 45.7 (± 13.1) 44.6 (± 7.9) 0.83 33.8 (± 6.4) 51.3 (± 16.7) 0.12 
Total CD4
+ 
(cells/µL) 694 (± 492) 500 (± 274) 0.33 463 (± 169) 611 (± 326) 0.21 
% CD8
+
 26.9 (± 4.0) 25.6 (± 5.7) 0.61 20.5 (± 7.1) 17.6 (± 8.6) 0.31 
Total CD8
+ 
(cells/µL) 396 (± 231) 318 (± 222) 0.12 270 (± 100) 204 (± 119) 0.15 
 
 
Low-dose CYC Decreases Tumor MVD in Canine STS 
 Tumor MVD was evaluated at each time point to assess whether low dose CYC 
exhibits antiangiogenic properties in canine STS.  This was assessed by measuring the 
tumor MVD in serial tumor biopsies for each patient. There were no significant changes 
in the mean tumor MVD between the three study time points in the tumors of dogs 
treated with 12.5 mg/m
2
/day CYC (Figure 3.5A).  However, in the dogs receiving CYC at 
15.0 mg/m
2
/day, the mean tumor MVD significantly decreased from a pretreatment mean 
of 2.6 (± 0.9)% to a mean of 1.3 (± 1.0)% on day 14 (P = 0.015).  This decrease persisted 
through day 28 (1.8 ± 0.8%) and was also significantly lower than the MVD prior to 
therapy (P = 0.004, Figure 3.5B).  The mean percent MVD was not significantly different 
between day 14 and day 28 in the 15.0 mg/m
2
/day dose cohort.   
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Low-Dose CYC Does Not Alter CEC 
 CEC isolated from peripheral blood were analyzed at each time point in this study 
as another means of assessing antiangiogenic properties of low-dose CYC.  As shown in 
Fig 3.6, there were no significant change in the absolute number or percentage of CEC at 
any time point for either the 12.5 mg/m
2
/day or the 15.0 mg/m
2



















































Figure 3.5: Tumor microvessel density (MVD) is significantly decreased in the 15.0 mg/m2/day 
cohort. Percentage of CD146+ cells in canine soft tissue sarcoma as an assessment of tumor MVD in dogs 
treated with metronomic cyclophosphamide (CYC).  (A) The mean tumor MVD (long horizontal lines) on 
days 0, 14, and 28 for dogs treated with 12.5 mg/m2/day CYC (n = 4) did not change significantly over the 
28 day study period as assessed by an paired, one-tailed t-test.  (B) The mean tumor MVD (long horizontal 
lines) in STS of dogs treated with 15.0 mg/m2/day CYC (n = 3) significantly decreased from day 0 to 14 (P 








































































































Figure 3.6: Circulating endothelial cells (CEC) are not altered in dogs with soft tissue sarcoma (STS) 
over 28 days of low dose cyclophosphamide in either dose cohort. The mean percentage (long horizontal 
line) of CEC for day 0, 14, and 28 was plotted in (A &C) and the mean of the absolute number (long 
horizontal line) of CEC was plotted in (B & D).  The CEC data from the 12.5 mg/m2/day cohort is shown in 
figures A & B and the 15.0 mg/m2/day cohort in C & D. There were no significant differences in CEC 
between any of the time points in any of the groups as assessed by paired, one-tailed t-test. 
 
DISCUSSION 
 Several important findings emerged from this investigation.  First, when 
compared with a population of healthy dogs, the blood of dogs with STS contained 
significantly increased numbers of Treg.  When dogs with STS received oral CYC at a 
dosage of 15 mg/m
2
/day, Treg numbers declined over the 28 day study period to that 
observed in healthy dogs.  In addition, daily administration of CYC at 15 mg/m
2
 was 
associated with a significant decrease in the density of blood vessels within tumor tissues 
from these patients, suggesting that metronomic delivery of CYC at this dosage has both 
immunomodulatory and antiangiogenic effects. 
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Previous work has established that Treg are increased in humans with a wide 
range of malignancies including melanoma, carcinoma of the ovaries, pancreas, breast 
and liver, and a number of hematologic malignancies; however, increases in Treg in 
humans with STS have not been previously described.
11,31
  Recent reports suggest that 
Treg are also increased in the blood of dogs with various cancers including melanoma, 
lymphoma and osteosarcoma.
13-16,32
  Although the results of the present study support the 
notion that circulating Treg are increased in dogs with cancer, conflicting reports exist in 
the veterinary literature, likely reflecting differences in experimental approach and the 
small numbers of dogs evaluated to date.
33
  
 A key finding of this study is that the administration of CYC at 15 mg/m
2
/day 
over the 28 day study period selectively decreases absolute numbers and percent of Treg 
in the peripheral blood of dogs with STS.  Dosages of CYC used in previously published 




   In two of these studies, metronomic 
chemotherapy appeared to have antineoplastic effects but the mechanism of action of the 
drugs used was not investigated.
21,22
  Our data suggest that decreased numbers of 
circulating Treg may be one potential antitumor activity of metronomic CYC therapy.  
Recent work demonstrates decreased levels of intracellular ATP in murine and human 
Treg as compared to other CD4
+
 T cells; lower levels of ATP and subsequent decreased 
glutathione levels contribute to low dose CYC Treg depletion.
34
  Whether this is the case 
in canine Treg is not known.  
 Serial changes in tumor MVD were used in this study to assess the 
antiangiogeneic properties of metronomic CYC therapy. We found that MVD was 





/day to dogs with STS.  This finding is consistent with previous work in 
other species that has established the antiangiogenic properties of metronomic dosing of 
CYC.
40,49,50
   Our findings should be interpreted with caution, however, as tumor MVD  
may not be the most accurate assessment of response to antiangiogenic therapy.
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Additionally, there was no significant change in the CEC population in this study 
suggesting that low-dose CYC may not inhibit angiogenesis by decreasing CEC.  CEC 
comprise a small fraction of circulating cells and detection of clinical relevant changes 
may be difficult to accomplish with this small sample size.  Further work should be 
performed in a larger population of dogs to more fully understand the possible effects of 
metronomic CYC on CEC. Combining evaluation of tumor MVD with other markers of 
angiogenesis such as vascular endothelial growth factor (VEGF) concentrations may 
provide greater understanding of the antiangiogenic properties of metronomic CYC in 
dogs with cancer. 
 Interestingly, significant decreases in both Treg numbers and tumor MVD 
occurred in dogs with STS treated with CYC at 15.0 mg/m
2
/day.  One explanation for 
this is that alterations in tumor immunity and angiogenesis occur at a similar dose of 
CYC.  This finding is in line with previous investigations in murine tumor models in 
which metronomic delivery of drugs such as CYC and paclitaxel were associated with 
both immunomodulatory and antiangiogenic effects.
38
   In a previously published study 
examining the impact of metronomic chemotherapy on incompletely excised STS in 




  Although our 
preliminary work indicated that decreases in Treg numbers do not occur at this dosage it 
is possible that the addition of piroxicam in the Elmslie study had a synergistic effect on 
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Treg depletion. Our data also suggests that Treg decreases may occur at dosages less than 
15.0 mg/m
2
/day because of the decrease in the absolute numbers of Treg observed in 
dogs receiving 12.5 mg/m
2
/day CYC; larger numbers of dogs will be required to optimize 
metronomic dosing of CYC.   
 Surface staining for CD4 and detection of the intracellular transcription factor 
FoxP3 were used in this study to identify canine Treg by flow cytometry similar to the 
method use in earlier studies.
13-15
  In addition to these markers, CD25, the alpha chain of 
the IL-2 receptor, is also commonly used to identify Treg in other species.  Recently both 
an anti-human CD25 antibody and a canine anti-CD25 antibody have been found to be 
useful in the identification of canine Treg.
33,39
  These antibodies were not available for 
use in the dogs of the present study; however, future studies should include the use of one 







 No adverse events were reported for any of the patients in this study.  This result 
is in contrast to previous studies examining metronomic chemotherapy protocols for 
canine malignancies that have reported that up to 23% of dogs develop grade 1 or 2 
gastrointestinal toxicity and 10-22% of patients developed sterile hemorrhagic cystitis 
(SHC) when CYC is administered.
21,22
  Both of these studies included the use of a non-
steroidal anti-inflammatory drug (NSAID) so it is possible that the gastrointestinal signs 
were secondary to the NSAID rather than the low dose CYC.  A limitation of the current 
study is that routine monitoring of urine was not performed to assess the presence of 
microscopic hematuria; however, clinical signs consistent with the development of SHC 
were not reported in any of the patients.  This is may be due to the short duration of CYC 
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administration here as dogs receiving long term therapy CYC at the MTD have a reported 
incidence of up to 10%.
40
 
 In addition to the occurrence of SHC, there are other potential complications of 
Treg prolonged depletion that should be investigated. Under non-neoplastic conditions, 
Treg function to prevent autoimmunity and therefore it is possible that chronic Treg 
depletion could lead to the development of autoimmune diseases.  Autoimmunity 
secondary to Treg depletion has been demonstrated in murine models; whether this may 
develop secondary to Treg modulation in dogs is currently unknown.
41,42
  
 In conclusion, we found that dogs with STS have significantly more Treg in 
circulation than healthy dogs.  Additionally, CYC administered at 15.0 mg/m
2
/day 
selectively decreased the number and percentage of Treg in the peripheral blood and 
appears to have some antiangiogenic properties in dogs with STS.  Due to the small 
number of dogs in this study, these results must be considered preliminary but support 
further studies to better characterize the antitumor effects and optimal dosing of low dose 
CYC in canine cancer therapy.  Additional studies will require longer treatment of a 
larger number of dogs to gain valuable information regarding potential biomarkers of 
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 The work contained within this thesis is intended to further the knowledge 
regarding the role of regulatory T cells (Treg) in canine cancer. In chapter two, we 
investigated the distribution of Treg in the peripheral blood, distant and tumor draining 
lymph nodes, and the tumor of dogs with osteosarcoma (OSA) as compared to the blood 
and lymph nodes of healthy control dogs. In addition, we also examined whether an 
association exists between Treg amounts in these tissue compartments and outcome of 
dogs with OSA. We demonstrated that a high intratumoral CD8/Treg ratio in dogs with 
OSA was positively correlated with disease-free interval (DFI) and overall survival (OS). 
This may indicate that Treg are increased and CD8+ T cells decreased in more advanced 
or aggressive OSA and that tumor infiltrating lymphocytes may have a role in the 
progression of this tumor type. We also found that circulating Treg are not increased as 
compared to Treg in the blood of healthy dogs.  As this finding is in contrast to 
previously published results, it raises the question as to whether use of non-steroidal anti-
inflammatory drugs (NSAID) may inhibit Treg as well. The concomitant use of NSAID 
in this study described in chapter two prevents definitive conclusions regarding the up 
regulation of Treg in dogs with OSA, but it identifies an area of further research 
regarding additional mechanisms of Treg inhibition in canine cancer. Finally, Treg were 
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not increased in distant or tumor draining lymph nodes in dogs with OSA.  This finding 
may relate to the biologic behavior of canine OSA in which lymph node metastasis is 
uncommon. Alternatively, normal Treg amounts in lymph nodes of dogs with OSA may 
be additional evidence that Treg may not play an important role in progression of OSA, 
particularly when combined with the finding that circulating Treg are not increased in 
dogs with OSA. T lymphocyte subsets in normal canine lymph nodes as well as Treg in 
multiple tissue compartments of dogs with OSA needs to be evaluated in a larger number 
of dogs before definitive conclusions may be made. 
In chapter three, we examined whether metronomic cyclophosphamide (CYC) has 
immunomodulatory and/or antioangiogenic properties in canine cancer.  Dogs with soft 
tissue sarcoma (STS) where enrolled in this study as this tumor type was easily amenable 
to repeated biopsy for assessment of microvessel density (MVD) and delay of definitive 
therapy for a 28 days period would not negatively impact the outcome of these dogs. In 
this study, we found that circulating Treg in dogs with STS were increased as compared 
to healthy dogs.  Alterations in Treg in the blood of dogs with STS have not been 
previously reported; Treg in the lymph nodes and tumors could not be consistently 
assessed in this study.  We determined that metronomic CYC administered at doses of 
15.0 mg/m
2
/day selectively decreased Treg, whereas lower dose of 10.0 and 12.5 
mg/m
2
/day did not. Additionally, the higher dose of daily CYC decreased tumor MVD, 
but not circulating endothelial cells (CEC); this provides some preliminary information 
that metronomic CYC may inhibit angiogenesis. 
As a whole, this work has identified alterations in Treg numbers in cancer bearing 
dogs and demonstrates that Treg levels may have prognostic value when evaluated in 
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combination with numbers of other effector T cells.  Additionally, we have shown that 
Treg can be decreased with metronomic dosing of CYC.  Decreases in Treg may be one 
of the anti-tumor mechanisms of metronomic CYC therapy; additional work needs to be 




 The work outlined in this thesis identified a number of additional areas of 
research regarding the role of Treg in canine cancer.  One potential area of further study 
is the effect of NSAID use and subsequent cyclooxygenase-2 (COX-2) inhibition on Treg 
populations in canine cancer. NSAID are commonly used in cancer therapy, not only for 
pain control but for anti-tumor effects as well.
1,2
 COX-2 is up regulated in many tumor 
type and this increased COX-2 expression has been associated with increases in Treg 
numbers as well.
3,4
  Treg numbers were not significantly increased in dogs with OSA as 
compared to healthy control dogs in this work, but most dogs received therapy with 
NSAID prior to and during the clinical trial. Prospective studies examining changes in 
Treg in dogs that are treated with an NSAID alone, metronomic CYC alone, or a 
combination of the two should be performed to determine the effects of NSAID on Treg 
and to explore whether the combination of NSAID and CYC may have synergistic 
activity in decreasing Treg in cancer-bearing dogs. 
 Increased frequencies of Treg are commonly associated with shortened disease-
free intervals and survival for a number of human malignancies.
5-8
 This association does 
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not always hold true, however, particularly for hematologic cancers such as lymphoma 
where several studies have shown that increased frequencies of Treg are positively 
correlated with outcome.
9,10
 A small population of dogs with lymphoma has previously 
been shown to have an elevated Treg/CD8 ratio as compared to other canine tumor types, 
but the prognostic significance of this finding is unknown.
11
 Further work needs to be 
performed to assess Treg populations in larger numbers of dogs with various tumor types 
and to correlate these findings with patient outcome in order to better understand the role 
of Treg in canine tumor immunity. 
 Our knowledge regarding Treg distribution in canine cancer patients remains 
limited. Further investigation into numbers of Treg and other effector T cell populations 
in tumors and tumor draining lymph nodes (TDLN) would allow a better understanding 
of the role of Treg in cancer progression. Work performed in this thesis focused on dogs 
with sarcomas, which have not been widely researched in humans. As carcinomas tend to 
readily spread to the TDLN, it would be intersting to examine Treg frequency within 
blood, tumors, and the TDLN of dogs with sarcomas as compared to carcinomas. If 
differences in Treg distributions exist between sarcomas and carcinomas, this may speak 
to differences in the biologic behavior of these cancers. 
 This research supports the theory that Treg populations are altered in canine 
cancer and these changes may provide prognostic information for dogs.  It is unknown 
whether Treg modulation may provide a clinical benefit for cancer-bearing dogs but we 
have provided preliminary evidence that metronomic dosing of CYC may decrease Treg 
frequencies in dogs with cancer.  This work is a small step forward in understanding the 
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involvement Treg may have in canine cancer and, combined with previous research on 
canine Treg, sets the foundation for additional studies in this field. 
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